A need for evidence-based clinical practice guidelines for the use of heparins in the elderly

Commentary

(2027) Views  (705) Full article downloads

Authors: Isabelle Gouin-Thibault, Virginie Siguret, Eric Pautas

Published Date April 2010 Volume 2010:5 Pages 119 - 121

DOI: http://dx.doi.org/10.2147/CIA.S9760

Isabelle Gouin-Thibault^1,2, Virginie Siguret^1,2, Eric Pautas^2,3

¹Assistance Publique Hôpitaux de Paris, Laboratoire d’Hématologie, Hôpital Charles Foix, Paris, France; ²Université Paris Descartes, INSERM U, Paris, France; ³Assistance Publique Hôpitaux de Paris, Unité de Gériatrie Aiguë, Hôpital Charles Foix, Paris, France

Abstract: Low-molecular-weight heparins (LMWHs) have been widely studied in pivotal clinical trials or in several meta-analyses. However, the safety and optimal use of LMWHs in high-risk patients such as the very elderly remains uncertain since these patients are usually excluded from clinical trials. In terms of LMWHs in the elderly, the main concerns are renal failure and the risk of accumulation. A clinical approach consisting of a LMWH dose reduction in the elderly should be considered with great caution in terms of efficacy, since it has been tested neither in the treatment of VTE nor in VTE prophylaxis. If monitoring is considered in patients receiving therapeutic dose LMWHs, appropriate target ranges for peak anti-Xa activity levels should be used and so far, no anti-Xa activity-based guidelines have been issued. Moreover, no data support any laboratory monitoring in elderly patients treated with prophylactic dose LMWHs.

Keywords: elderly patients, low-molecular-weight heparin, renal insufficiency, evidence-based medicine